Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Vasotec Generic Name & Formulations
Legal Class
Rx
General Description
Enalapril maleate 2.5mg, 5mg, 10mg, 20mg; scored tabs.
Pharmacological Class
ACE inhibitor.
How Supplied
Tabs 2.5mg, 5mg—30, 90; 10mg, 20mg—30, 90, 1000
Manufacturer
Generic Availability
YES
Vasotec Indications
Indications
Symptomatic CHF, usually with digitalis and diuretics. Asymptomatic left ventricular dysfunction (ejection fraction ≤35%).
Vasotec Dosage and Administration
Adult
Initially 2.5mg 1–2 times daily. May increase to 5–20mg daily in 1–2 divided doses; max 40mg/day. Reduce diuretic dosage before 1st dose, if possible; observe patient for at least 2 hrs after 1st dose, until BP has stabilized for at least 1 hr. CHF with hyponatremia or renal dysfunction: see literature. Left ventricular dysfunction: Initially 2.5mg twice daily; max 20mg daily in divided doses.
Children
Not established.
Vasotec Contraindications
Contraindications
History of ACEI-associated or other angioedema. Concomitant neprilysin inhibitors (eg, sacubitril); do not administer lisinopril within 36hrs of switching to or from sacubitril/valsartan. Concomitant aliskiren in patients with diabetes.
Vasotec Boxed Warnings
Boxed Warning
Fetal toxicity.
Vasotec Warnings/Precautions
Warnings/Precautions
Fetal toxicity may develop; discontinue if pregnancy is detected. Renal impairment. Salt/volume depletion. CHF. Ischemic disease. Cerebrovascular disease. Dialysis (esp. high-flux membrane). Renal artery stenosis. Surgery. Diabetes. Monitor WBCs in renal or collagen vascular disease. Discontinue if neutropenia, angioedema, laryngeal edema, jaundice or marked elevations of hepatic enzymes develop. Monitor BP, electrolytes and renal function. Black patients may have higher rate of angioedema than non-Black patients. Neonates. Pregnancy, nursing mothers: not recommended.
Vasotec Pharmacokinetics
See Literature
Vasotec Interactions
Interactions
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). Potentiated by, and hypotension with, diuretics. Hyperkalemia with K+-sparing diuretics, K+ supplements, or K+-containing salt substitutes. May increase lithium levels. May be antagonized by, and renal toxicity potentiated by NSAIDs, including COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted). Increased risk of angioedema with concomitant mTOR inhibitors (eg, temsirolimus, sirolimus, everolimus) or neprilysin inhibitors. Nitritoid reactions with concomitant injectable gold (eg, sodium aurothiomalate); rare.
Vasotec Adverse Reactions
Adverse Reactions
Cough, headache, dizziness, fatigue, diarrhea, rash, orthostatic hypotension, asthenia, hyperkalemia, renal impairment, nausea; rare: hepatic failure.
Vasotec Clinical Trials
See Literature
Vasotec Note
Not Applicable
Vasotec Patient Counseling
See Literature
Vasotec Generic Name & Formulations
Legal Class
Rx
General Description
Enalapril maleate 2.5mg, 5mg, 10mg, 20mg; scored tabs.
Pharmacological Class
ACE inhibitor.
How Supplied
Tabs 2.5mg, 5mg—30, 90; 10mg, 20mg—30, 90, 1000
Manufacturer
Generic Availability
YES
Vasotec Indications
Indications
Hypertension.
Vasotec Dosage and Administration
Adult
If on diuretics or CrCl <30mL/min: suspend diuretic for 2–3 days, if possible: initially 2.5mg daily; max 40mg. Monitor closely for first 2 wks. Others: initially 5mg daily. Usual range: 10–40mg daily in 1–2 divided doses.
Children
Neonates or CrCl <30mL/min: not established. Initially 0.08mg/kg (up to 5mg) once daily; max 0.58mg/kg (or 40mg) daily. Suspension form may be prepared if unable to swallow tabs: see full labeling.
Vasotec Contraindications
Contraindications
History of ACEI-associated or other angioedema. Concomitant neprilysin inhibitors (eg, sacubitril); do not administer lisinopril within 36hrs of switching to or from sacubitril/valsartan. Concomitant aliskiren in patients with diabetes.
Vasotec Boxed Warnings
Boxed Warning
Fetal toxicity.
Vasotec Warnings/Precautions
Warnings/Precautions
Fetal toxicity may develop; discontinue if pregnancy is detected. Renal impairment. Salt/volume depletion. CHF. Ischemic disease. Cerebrovascular disease. Dialysis (esp. high-flux membrane). Renal artery stenosis. Surgery. Diabetes. Monitor WBCs in renal or collagen vascular disease. Discontinue if neutropenia, angioedema, laryngeal edema, jaundice or marked elevations of hepatic enzymes develop. Monitor BP, electrolytes and renal function. Black patients may have higher rate of angioedema than non-Black patients. Neonates. Pregnancy, nursing mothers: not recommended.
Vasotec Pharmacokinetics
See Literature
Vasotec Interactions
Interactions
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). Potentiated by, and hypotension with, diuretics. Hyperkalemia with K+-sparing diuretics, K+ supplements, or K+-containing salt substitutes. May increase lithium levels. May be antagonized by, and renal toxicity potentiated by NSAIDs, including COX-2 inhibitors (monitor renal function periodically in elderly and/or volume-depleted). Increased risk of angioedema with concomitant mTOR inhibitors (eg, temsirolimus, sirolimus, everolimus) or neprilysin inhibitors. Nitritoid reactions with concomitant injectable gold (eg, sodium aurothiomalate); rare.
Vasotec Adverse Reactions
Adverse Reactions
Cough, headache, dizziness, fatigue, diarrhea, rash, orthostatic hypotension, asthenia, hyperkalemia, renal impairment, nausea; rare: hepatic failure.
Vasotec Clinical Trials
See Literature
Vasotec Note
Not Applicable
Vasotec Patient Counseling
See Literature
